Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio ...

The MarketWatch News Department was not involved in the creation of this content. IFLI backs CIT's pioneering approach to accelerate the development of innovative treatments for follicular lymphoma ...

Epcoritamab monotherapy achieved high overall (84.6%) and complete response rates (67.1%) in relapsed/refractory follicular lymphoma patients with multiple prior therapies. Combination therapy with ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Real-world treatment patterns and outcomes among older patients with follicular lymphoma show significant heterogeneity, with 13,423 Medicare beneficiaries aged ≥ 65 years followed through 2019. Over ...

DIAMOND BAR, Calif., Aug. 13, 2025 /PRNewswire/ -- CIT Therapeutics, Inc. (CIT), a biotechnology company focused on developing next-generation small molecule therapies targeting SUMOylation for cancer ...

At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for patients with previously untreated follicular lymphoma with a high tumor ...

Important facts to keep in mind. re than 30 million Americans have a thyroid disorder and an excess of 60,000 Americans are affected by thyroid cancer annually. — -- intro: You probably don't ...